Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Item

http://www.wikidata.org/entity/Q34128082

Q34128082

about

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity Vector transmission of leishmania abrogates vaccine-induced protective immunity Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters Vaccines to combat the neglected tropical diseases.Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.Identifying vaccine targets for anti-leishmanial vaccine development Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.CD8(+) T cells in leishmania infections: friends or foes?Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells Adjuvants for Leishmania vaccines: from models to clinical application.Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis Differential Immune Response against Recombinant Leishmania donovani Peroxidoxin 1 and Peroxidoxin 2 Proteins in BALB/c Mice.Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine Kinetoplastids: related protozoan pathogens, different diseases.Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery.Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.Cutaneous leishmaniasis: progress towards a vaccine.Optimized subunit vaccine protects against experimental leishmaniasis.Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.Use of defined TLR ligands as adjuvants within human vaccines.

P2860

Q27305883-A12E82B3-F901-404D-8384-380E6DD0CB7D Q27312070-F9605412-14D9-4895-9C04-A57609B9F62E Q27316727-C93EDADB-7A80-4480-B407-C654B3C0B22C Q28480398-57ACF60B-BD7D-4868-883B-04D7410ECBE4 Q30425005-0A0F8B75-43D6-4642-90BF-40208A86206D Q30444062-A2BA290C-E137-40A4-9E19-BDD4266AB6AE Q33693899-AA1675FC-D2C6-4871-B603-E575C60A633F Q33753259-4BACB7B9-9158-47C0-8022-2A116DE40923 Q33870336-E69FA7FB-8C20-40BD-B551-1C5E4BB81BE4 Q34068700-AA1D3818-5880-40F4-B59D-FB909A09F12B Q34235741-D43A813B-4553-4D4A-ACE1-F9A3E65C3F73 Q34277331-7365DF1F-C163-45FA-81E1-D43A522CF1DD Q35029988-A3BB860F-89AF-4373-BF7A-673C9A0524DB Q35138682-04D9719D-4075-436B-B585-03A3C546F966 Q35198753-BA4300AD-B156-4B51-875F-F5978CE5B15D Q35532405-36C1D1D2-4C1B-4270-90EF-7E93606DF298 Q35809113-3DA36F1C-B658-45E3-A1BA-31105DFD5160 Q35927465-9D5A03D1-C7C6-451D-B44D-EBF9DFC7D6C3 Q35947234-DDE8C560-7B91-48C5-8AE9-60D2B575A6CB Q36021357-6D398832-FB06-4D47-B428-E31511CB84CF Q36025524-EDBCDDDC-3F98-4163-B2C1-0C1BB99B5479 Q36035026-7FBDAAB5-965F-4AF7-9CF1-B4877E77B589 Q36105743-68456BF9-6174-41C1-B845-9F3B8246C9A8 Q36141819-63A15433-E23B-4241-928D-A7A1D0126DF5 Q36369774-8281F49C-87B5-43A1-A656-E3692A966848 Q36376098-0E66AC51-EB8B-4BF3-9FE5-F03C25733B44 Q36376320-C7BFD5C2-F286-4009-B181-FFE88297C116 Q36484748-611D5CD3-E26E-420B-93B8-CED6838D2504 Q36513308-042FB36D-8F67-4750-8007-393E2AF5795B Q36539044-542DFD24-CAC8-44CF-8C24-AB6B40D5959A Q36682576-DE1B4B9C-953F-4015-95FE-2FDF1C973AEE Q36958635-12E212A5-FFFA-46DC-80CF-3CB260DA2B57 Q36994297-EBABE523-D2AA-4211-992E-F407B05E3739 Q37109519-DE70091E-5C36-4523-9A6C-C8310D2CD564 Q37223654-852EA51D-14C0-447B-88E5-226EC56AF508 Q37225443-4EC8C5AD-AF47-4051-9B31-E74E686B695D Q37290119-0866575A-2953-49C0-B3C8-C3E8138FBB7A Q37439440-8DC2CB2F-1188-445A-B1CE-BD250E125F48 Q37523834-EB663EA4-D791-43C0-9D9E-C3F4AD6BD941 Q37825528-38F6687D-27C5-4456-8224-B22DAE080899

P2860

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

Item

http://www.wikidata.org/entity/Q34128082

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu